ARCT News and Press, Arcturus Therapeutics Ltd. From 08/03/21

Shares of Arcturus Therapeutics (NASDAQ: ARCT) were soaring 34.7% higher as of 10:56 a.m. EDT on Tuesday. The big jump came after the company announced that Singapore regulators approved the advancement of two messenger RNA COVID-19 vaccine candidates into phase 1/2 clinical testing...

Gainers: Arcturus Therapeutics ARCT +35%, Translate Bio TBIO +29%, Flora Growth (NASDAQ:FLGC) +27%, Lixte Biotechnology (NASDAQ:LIXT) +27%, Outlook Therapeutics (NASDAQ:OTLK) +23%. Losers: Neuronetics STIM -39%, Bright Health BHG -19%,&#x...

Arcturus Therapeutics (NASDAQ:ARCT) has received approval for a Clinical Trial Application (CTA) from the Singapore Health Sciences Authority (HSA) to enable the advancement of two STARR mRNA vaccine candidates into the clinic. Shares of the company up nearly 7% premarket. The Phase...

Singapore is the second country to approve the advancement of ARCT-154 into clinical development ARCT-154 and ARCT-165 elicit high levels of neutralizing antibodies in non-human primates against multiple variants of concern Arcturus Therapeutics Holdings Inc. (the &#...

The Phase 1/2/3 trial to be funded and sponsored by Arcturus’ manufacturing partner Vinbiocare ARCT-154 to be developed in parallel with ARCT-021, Arcturus’ lead investigational COVID-19 vaccine Arcturus Therapeutics Holdings Inc. (the “Company&#...

Arcturus Therapeutics Holdings (NASDAQ:ARCT) announces an agreement with Vinbiocare Biotechnology Joint Stock Company regarding a collaboration to establish a manufacturing facility in Vietnam for the manufacture of Arcturus’ investigational COVID-19 vaccines, for sale and use within V...

Arcturus will receive $40 million upfront payment and potential royalties based on vaccines produced Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on...

Arcturus Therapeutics (ARCT) announces that the company has received approval from the UK Health Research Authority to initiate a Phase 2 study for ARCT-810, a novel mRNA-based therapeutic candidate for Ornithine Transcarbamylase ((OTC)) Deficiency.OTC deficiency is a serious urea cycle disor...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT) a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare di...

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare d...